title: The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
abstract: Calcimimetics increase the sensitivity of the calcium-sensing receptor (CaR) to circulating serum calcium, reducing the secretion of PTH and the serum calcium concentration. We evaluated the calcimimetic cinacalcet, a novel therapy for the management of primary hyperparathyroidism. In this randomized, double-blind, dose-finding study, patients (n = 22) with primary hyperparathyroidism were given cinacalcet (30, 40, or 50 mg) or placebo twice daily for 15 d and observed for an additional 7 d. Serum calcium, plasma PTH, and 24-h and fasting urine calcium were measured. Baseline mean serum calcium was 10.6 mg/dl for the combined cinacalcet-treated patients (normal range, 8.4-10.3 mg/dl), compared with 10.4 mg/dl for the placebo group. Mean PTH at baseline was 102 pg/ml (normal range, 10-65 pg/ml) for the combined cinacalcet-treated patients, compared with 100 pg/ml in the placebo group. Serum calcium normalized after the second dose on d 1 and remained normal through d 15 in all cinacalcet dose groups. Maximum decreases in PTH of over 50% occurred 2-4 h after dosing in all cinacalcet-treated groups. The fasting and 24-h urine calcium to creatinine ratios were similar in the cinacalcet and placebo groups. This study demonstrates that cinacalcet safely normalized serum calcium and lowered PTH concentrations without increasing urinary calcium excretion in the study subjects, indicating the potential benefit of cinacalcet as a medical treatment for primary hyperparathyroidism.
authors.affiliation: Department of Medicine, Veterans Affairs Medical Center, University of California-San Francisco, San Francisco, California 94121, USA. Dolores@itsa.ucsf.edu
authors.forename: Dolores M
authors.initials: DM
authors.lastname: Shoback
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
authors.forename: Stewart A
authors.initials: SA
authors.lastname: Turner
authors.forename: Laura C
authors.initials: LC
authors.lastname: McCary
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Guo
authors.forename: Munro
authors.initials: M
authors.lastname: Peacock
mesh_terms: D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood* / Q000652:urine; D000069449:Cinacalcet; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood* / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009994:Osmolar Concentration; D010281:Parathyroid Hormone / Q000097:blood; D013997:Time Factors
chemical_list: D009281:Naphthalenes; D010281:Parathyroid Hormone; D002118:Calcium; D000069449:Cinacalcet